Cargando…

Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and neck cancer is the 6(th) most common cancer worldwide with the most common histology being squamous cell carcinoma (HNSCC). While the majority of patients present at a stage where curative intent therapy is possible, when patients recur and/or develop metastatic disease, outcomes are genera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsieh, Ronan W., Borson, Steven, Tsagianni, Anastasia, Zandberg, Dan P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440813/ https://www.ncbi.nlm.nih.gov/pubmed/34540672 http://dx.doi.org/10.3389/fonc.2021.705614

Ejemplares similares

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Argiris, Athanassios, et al.
Publicado: (2017)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Taberna, Miren, et al.
Publicado: (2019)

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Borel, Christian, et al.
Publicado: (2020)

Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK
por: Uozumi, Shinya, et al.
Publicado: (2018)

Combination immunochemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and meta-analysis
por: Xu, Qiudong, et al.
Publicado: (2023)

The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapy
por: Damasio, Marcos Paulo S., et al.
Publicado: (2022)

Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: the emergence of immunotherapy
por: Faraji, Farhoud, et al.
Publicado: (2023)

Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa
por: Yang, Chuan-Chien, et al.
Publicado: (2022)

The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions
por: Guigay, Joël, et al.
Publicado: (2019)

Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors
por: Arribas, Lorena, et al.
Publicado: (2021)

Definitive local therapy to head and neck squamous cell carcinoma with distant metastasis
por: Borson, Steven, et al.
Publicado: (2022)

Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab
por: Pogorzelski, Michael, et al.
Publicado: (2021)

Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma
por: Flanagan, Kevin C., et al.
Publicado: (2023)

Exosomes in Head and Neck Squamous Cell Carcinoma
por: Xiao, Cheng, et al.
Publicado: (2019)

Cathepsins B, D, and G Are Expressed in Metastatic Head and Neck Cutaneous Squamous Cell Carcinoma
por: Humphries, Felix, et al.
Publicado: (2021)

The Regulation of Lymph Node Pre-Metastatic Niche Formation in Head and Neck Squamous Cell Carcinoma
por: Hu, Chen, et al.
Publicado: (2022)

New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Alberti, Andrea, et al.
Publicado: (2022)

TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck
por: Rubió-Casadevall, Jordi, et al.
Publicado: (2023)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
por: Cohen, Ezra E. W., et al.
Publicado: (2019)

Cancer Stem Cell Subpopulations Are Present Within Metastatic Head and Neck Cutaneous Squamous Cell Carcinoma
por: Kilmister, Ethan J., et al.
Publicado: (2020)

Positron Emission Tomography-Computed Tomography Parameters Predict Efficacy of Immunotherapy in Head and Neck Squamous Cell Carcinomas
por: Zhang, Songtao, et al.
Publicado: (2021)

Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma
por: Black, Christopher M., et al.
Publicado: (2023)

Complete Response to Nivolumab in Recurrent/Metastatic HPV-Positive Head and Neck Squamous Cell Carcinoma Patient After Progressive Multifocal Leukoencephalopathy: A Case Report
por: Locati, Laura Deborah, et al.
Publicado: (2022)

Corrigendum: Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma
por: Black, Christopher M., et al.
Publicado: (2023)

Immunotherapy for head and neck squamous cell carcinoma
por: Fuereder, Thorsten
Publicado: (2016)

Immunotherapy for Head and Neck Squamous Cell Carcinoma
por: Moskovitz, Jessica, et al.
Publicado: (2018)

Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and Neck
por: Szturz, Petr, et al.
Publicado: (2016)

Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma
por: Van Gestel, Dirk, et al.
Publicado: (2020)

Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma
por: Sobol, Robert E., et al.
Publicado: (2021)

Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands
por: van der Linden, Naomi, et al.
Publicado: (2015)

Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation
por: Wildsmith, Sophie, et al.
Publicado: (2022)

Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus
por: Wang, Huanhuan, et al.
Publicado: (2021)

Pattern of Recurrence After Platinum-Containing Definitive Therapy and Efficacy of Salvage Treatment for Recurrence in Patients with Squamous Cell Carcinoma of the Head and Neck
por: Wakasugi, Tetsuro, et al.
Publicado: (2022)

A Non Platinum Regimen for the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Region. Results From an Extended Phase II Study With Paclitaxel and Capecitabine
por: Bentzen, Jens K. D., et al.
Publicado: (2018)

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Wildsmith, Sophie, et al.
Publicado: (2023)

Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population
por: Chen, Wen-Chun, et al.
Publicado: (2017)

Pretreatment ADC is not a prognostic factor for local recurrences in head and neck squamous cell carcinoma when clinical T-stage is known
por: Peltenburg, Boris, et al.
Publicado: (2019)

Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group
por: Klinghammer, Konrad, et al.
Publicado: (2022)

Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
por: Cavalieri, Stefano, et al.
Publicado: (2021)

Cancer-Associated Fibroblast Density, Prognostic Characteristics, and Recurrence in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis
por: Knops, Alexander M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dq0lap31dae1b9hfbrqj7i6hg7